Tagged with

UAE Dr Emran Khan, an endocrinologist at King’s College Hospital Dubai, provides an overview of the prevalence of diabetes in the UAE after studies revealed that around 17 percent of the population suffers from the disease. Moreover, Dr Khan analyzes the country’s efforts to combat the disease and the role that…

Morocco Yassine Houbachi discusses his strategy for leading Moroccan generics player Polymedic, the market environment in Morocco, and what future challenges may be. In addition, Houbachi introduces RIM Pharma, an innovative young company which is expanding access to oncology diagnostics in Morocco.   The market being stagnant, prices are dropping and…

Romania Gabriel Cernica, general manager of Cegedim Customer Information and Cegedim Rx Romania, analyses the main trends shaping the pharmaceutical and healthcare environment in Romania and their effect on Cegedim’s business. He also shares Cegedim’s new product and service offering and how the company is tailoring them to specific stakeholder needs…

UAE Ayman Mokhtar is the general manager (GM) of GCC, Iraq and Iran for Upjohn, a Pfizer division. He spoke to us about his professional journey and Upjohn’s efforts to establish strategic public-private partnerships with actors including the Ministry of Health and Prevention (MoHAP) for a Centre of Excellence for Real…

Czech Republic In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working almost 30 years previously.   My goal is to continue reinvesting our profits to keep growing and leave behind a…

Czech Republic As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the 125-year-old German firm STADA has established a strong Czech affiliate in recent times.   The beauty of STADA is that…

Belgium Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to the latest EFPIA data. The country has a long-established tradition of excellence in clinical trials and AmCham Belgium estimates that…

UK With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life science investment destinations and multinational pharma firms including Novartis are already taking note.   “Tangible Opportunity” In February 2020, the…

Artificial Intelligence Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an antibiotic that is powerful enough to combat resistant bacteria strains via a deep learning algorithm.   AI has the power to enable biopharmaceutical companies to reduce costs and improve…

Romania Amalia Mihai, market access manager of Ipsen Romania explains that over the course of 26 years Ipsen has been increasingly helping Romanian patients in the field of oncology, neurodegenerative disorders, gastroenterology and endocrinology. She reveals that a successful market launch entails having a patient-centric approach, supporting patients not only with…

Opinion Blue Spoon Consulting’s John G. Singer* provides a thought-provoking outline of how the global health economy needs to evolve a new ‘systems framework’ to deal with the complexity and interconnectedness of healthcare today.   We need to unleash a new set of capabilities designed by a different level of thinking…

IFPMA Earlier this month, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) issued new guidance for the pharmaceutical industry on how it interacts with patients and patient organisations, with the aim of safeguarding patient interests across the world.   When money or resources are involved in interactions, we must at…